Convatec Group PLC (FRA:2CV)
Germany · Delayed Price · Currency is EUR | Market Cap | 5.22B -8.8% |
| Revenue (ttm) | 2.18B +5.7% |
| Net Income | 108.54M -43.0% |
| EPS | 0.05 -41.5% |
| Shares Out | n/a |
| PE Ratio | 48.14 |
| Forward PE | 14.55 |
| Dividend | 0.06 (2.56%) |
| Ex-Dividend Date | Aug 20, 2026 |
| Volume | n/a |
| Open | 2.560 |
| Previous Close | 2.660 |
| Day's Range | 2.560 - 2.560 |
| 52-Week Range | 2.140 - 2.920 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Convatec Group
Convatec Group PLC engages in the development, manufacturing, and sale of medical products, services and technologies for the management of chronic conditions in Europe, North America, and internationally. The company offers advanced wound care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorect... [Read more]
Financial Performance
In 2025, Convatec Group's revenue was $2.44 billion, an increase of 6.55% compared to the previous year's $2.29 billion. Earnings were $175.00 million, a decrease of -8.38%.
Financial numbers in USD Financial StatementsNews
ConvaTec Group H1 Earnings Call Highlights
ConvaTec Group LON: CTEC said it remained on track to meet its 2026 financial targets after reporting 5% organic revenue growth in the first half, excluding the impact of its InnovaMatrix skin-substit...
Convatec Group Earnings Call Transcript: H1 2026
H1 2026 saw solid revenue and EPS growth, with strong performance across all segments and new products scaling up. Guidance for FY 2026 is reaffirmed, with accelerated growth and margin expansion expected in H2, supported by robust order visibility and ongoing productivity initiatives.
Convatec Group Quarterly report: H1 2026
Convatec Group has published its H1 2026 quarterly earnings report on August 4, 2026.
Convatec Group Slides: H1 2026
Convatec Group has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 4, 2026.
UK's Convatec expects higher second-half margin, launches $200 million buyback
British medical products maker Convatec on Tuesday forecast its second-half operating margin to be materially higher than the first half, and pointed to accelerating demand for its infusion care pro...
Medical product maker Convatec warns of higher cost from Iran War
British medical products maker Convatec on Thursday posted slower organic revenue growth for the first four months of 2026 and its CEO warned of higher costs in 2027 due to the Iran conflict, sendin...
Convatec Group Transcript: Trading update
Broad-based growth across all categories supports unchanged 2026 guidance, with new product launches and capacity expansions expected to accelerate growth from 2027. Margin and EPS targets remain on track, despite inflation and regulatory uncertainties.
Convatec Group Earnings release: Trading update
Convatec Group released its earnings on May 21, 2026, summarizing the period's financial results.
Convatec Group Slides: Trading update
Convatec Group has posted slides in relation to its latest quarterly earnings report, which was published on May 21, 2026.
Convatec's Advanced Wound Care Innovation Leads the Industry at European Wound Management Association (EWMA) 2026
LONDON--(BUSINESS WIRE)--Convatec, a leading medical products and technology company focused on chronic condition management, takes to the stage to showcase the breadth, depth and momentum behind its ...
Convatec Group Transcript: CMD 2026
The Accelerate strategy builds on a successful turnaround, targeting 6%-8% organic revenue growth, mid-20s operating margin, and double-digit EPS growth. Growth is driven by robust innovation, new product launches across all categories, capacity expansion, and disciplined capital allocation.
Convatec Group Slides: FY 2026
Convatec Group has posted slides in relation to its FY 2026 quarterly earnings report, which was published on April 9, 2026.
Convatec Introduces Co-Branded eakin freeseal® Ostomy Seal in North America, Expanding the ESENTA™ Family of Accessories
BOSTON & LONDON--(BUSINESS WIRE)--Convatec, a leading medical products and technologies company focused on solutions for the management of chronic conditions, and Eakin Healthcare, a specialist provid...
Convatec Group Earnings Call Transcript: H2 2025
Delivered strong organic revenue and margin growth in 2025, with double-digit EPS increase and robust cash flow. 2026 guidance targets 5%-7% organic growth and at least 23% margin, despite reimbursement headwinds. From 2027, aims for 6%-8% annual growth and mid-twenties margin.
Convatec Group Annual report: H2 2025
Convatec Group has published its H2 2025 annual report on February 24, 2026.
Convatec Group Annual report: H2 2025
Convatec Group has published its H2 2025 annual report on February 24, 2026.
Convatec Group Slides: H2 2025
Convatec Group has posted slides in relation to its H2 2025 quarterly earnings report, which was published on February 24, 2026.
Convatec Group Transcript: Trading Update
Broad-based organic revenue growth and strong product launches underpin confidence in meeting 2025 and medium-term targets. Despite regulatory headwinds for InnovaMatrix, margin expansion and double-digit EPS growth are expected, supported by innovation and increased CapEx.
Convatec Group Earnings release: Trading Update
Convatec Group released its earnings on November 13, 2025, summarizing the period's financial results.
Convatec Group Slides: Trading Update
Convatec Group has posted slides in relation to its latest quarterly earnings report, which was published on November 13, 2025.